Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis

We describe a case of prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a patient receiving ocrelizumab for multiple sclerosis. Viral RNA shedding, signs, and symptoms persisted for 69 days with resolution after administration of convalescent plasma and antiviral th...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibson, Elena G, Pender, Melissa, Angerbauer, Michael, Cook, Craig, Jones, Barbara, Spivak, Adam M, Spivak, Emily S, Swaminathan, Sankar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083367/
https://www.ncbi.nlm.nih.gov/pubmed/34258310
http://dx.doi.org/10.1093/ofid/ofab176
_version_ 1783685991097171968
author Gibson, Elena G
Pender, Melissa
Angerbauer, Michael
Cook, Craig
Jones, Barbara
Spivak, Adam M
Spivak, Emily S
Swaminathan, Sankar
author_facet Gibson, Elena G
Pender, Melissa
Angerbauer, Michael
Cook, Craig
Jones, Barbara
Spivak, Adam M
Spivak, Emily S
Swaminathan, Sankar
author_sort Gibson, Elena G
collection PubMed
description We describe a case of prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a patient receiving ocrelizumab for multiple sclerosis. Viral RNA shedding, signs, and symptoms persisted for 69 days with resolution after administration of convalescent plasma and antiviral therapy. This case suggests risk for persistent SARS-CoV-2 infection in patients treated with anti-CD-20 monoclonal antibodies and supports a role for humoral immunity in disease resolution.
format Online
Article
Text
id pubmed-8083367
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-80833672021-05-03 Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis Gibson, Elena G Pender, Melissa Angerbauer, Michael Cook, Craig Jones, Barbara Spivak, Adam M Spivak, Emily S Swaminathan, Sankar Open Forum Infect Dis Brief Report We describe a case of prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a patient receiving ocrelizumab for multiple sclerosis. Viral RNA shedding, signs, and symptoms persisted for 69 days with resolution after administration of convalescent plasma and antiviral therapy. This case suggests risk for persistent SARS-CoV-2 infection in patients treated with anti-CD-20 monoclonal antibodies and supports a role for humoral immunity in disease resolution. Oxford University Press 2021-04-08 /pmc/articles/PMC8083367/ /pubmed/34258310 http://dx.doi.org/10.1093/ofid/ofab176 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Gibson, Elena G
Pender, Melissa
Angerbauer, Michael
Cook, Craig
Jones, Barbara
Spivak, Adam M
Spivak, Emily S
Swaminathan, Sankar
Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis
title Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis
title_full Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis
title_fullStr Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis
title_full_unstemmed Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis
title_short Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis
title_sort prolonged sars-cov-2 illness in a patient receiving ocrelizumab for multiple sclerosis
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083367/
https://www.ncbi.nlm.nih.gov/pubmed/34258310
http://dx.doi.org/10.1093/ofid/ofab176
work_keys_str_mv AT gibsonelenag prolongedsarscov2illnessinapatientreceivingocrelizumabformultiplesclerosis
AT pendermelissa prolongedsarscov2illnessinapatientreceivingocrelizumabformultiplesclerosis
AT angerbauermichael prolongedsarscov2illnessinapatientreceivingocrelizumabformultiplesclerosis
AT cookcraig prolongedsarscov2illnessinapatientreceivingocrelizumabformultiplesclerosis
AT jonesbarbara prolongedsarscov2illnessinapatientreceivingocrelizumabformultiplesclerosis
AT spivakadamm prolongedsarscov2illnessinapatientreceivingocrelizumabformultiplesclerosis
AT spivakemilys prolongedsarscov2illnessinapatientreceivingocrelizumabformultiplesclerosis
AT swaminathansankar prolongedsarscov2illnessinapatientreceivingocrelizumabformultiplesclerosis

Ejemplares similares